Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Recruiting

Study on Using Oxaliplatin, Fluorouracil, and Folinic Acid for Treating Stage II Colon Cancer in Patients with Positive Circulating Tumor DNA

Fast replyRegistered drug
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This clinical trial is focused on studying colon cancer, specifically stage II colon cancer. The trial aims to improve the chances of staying free from the disease after treatment by using a combination of medications. The treatment being tested is called FOLFOX6m, which includes three main drugs: oxaliplatin, fluorouracil, and folinic acid. These medications are given through a drip into a vein, known as an intravenous infusion.

The purpose of the study is to see if this combination of drugs can help patients who have a specific marker in their blood, called circulating tumor DNA (ctDNA), which indicates a higher risk of cancer returning. The study will compare the outcomes of patients who receive the FOLFOX6m treatment with those who do not, to determine if the treatment is effective in preventing the cancer from coming back.

Participants in the study will receive the treatment over a period of six months. During this time, they will be monitored regularly to check their health and see how well the treatment is working. The study will also look at how long it takes for the cancer to return, if it does, and the overall survival of the patients. The trial is expected to continue until March 2026, with the goal of improving the long-term health of patients with stage II colon cancer.

The research process

The trial runs in 6 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Joining the study

    Upon joining the study, a signed written informed consent is required. This consent confirms understanding and agreement to participate in the study.

    Eligibility is confirmed based on specific criteria, including age, health status, and previous treatments.

  2. Step 2

    Initial assessment

    An initial assessment is conducted to ensure all eligibility criteria are met. This includes blood tests and imaging to confirm the absence of metastatic disease.

    A negative pregnancy test is required for women of childbearing age.

  3. Step 3

    Randomization

    Participants are randomly assigned to different groups within the study. This process occurs up to 11 weeks after surgery.

  4. Step 4

    Treatment administration

    The treatment involves the administration of FOLFOX6m, which includes the medications oxaliplatin, fluorouracil, and folinic acid.

    These medications are given through intravenous perfusion and injection.

  5. Step 5

    Monitoring and follow-up

    Regular monitoring is conducted to assess the effectiveness of the treatment and to check for any side effects.

    Follow-up appointments are scheduled to evaluate Disease Free Survival (DFS) and other health outcomes.

  6. Step 6

    Completion of the study

    The study is estimated to conclude by March 31, 2026.

    Final assessments are conducted to gather data on the primary and secondary endpoints, including overall survival and time to recurrence.

Who can join the trial?

20 criteria

  • Signed written informed consent obtained before any study-specific procedures.
  • No previous chemotherapy for colon or rectal cancer.
  • No previous radiation treatment to the abdomen or pelvis for colon or rectal cancer.
  • Life expectancy of at least 5 years.
  • Good blood health: with neutrophils (a type of white blood cell) of at least 1,500 per cubic millimeter, platelet count of at least 100,000 per cubic millimeter, and hemoglobin (a protein in red blood cells) of at least 9 grams per deciliter.
  • Total bilirubin (a substance made by the liver) no more than 1.5 times the upper limit of normal.
  • ASAT and ALAT (liver enzymes) no more than 2.5 times the upper limit of normal.
  • Alkaline phosphatase (an enzyme related to the liver) no more than 2.5 times the upper limit of normal.
  • Serum creatinine (a waste product in the blood) no more than 120 micromoles per liter or creatinine clearance (a measure of kidney function) of at least 50 milliliters per minute.
  • Carcinoembryogenic antigen (CEA, a protein that may be higher in cancer) no more than 1.5 times the upper limit of normal after surgery.
  • Negative pregnancy test for women who can have children.
  • Age between 18 and 80 years. For patients 70 years or older, a score greater than 14 on the G8 geriatric questionnaire is required.
  • Patient must be part of a social security system.
  • Confirmed stage II colon and high rectum adenocarcinoma (a type of cancer) without remaining disease after surgery. The tumor must be located at least 12 cm from the anal verge or above the peritoneal reflection.
  • At least 12 lymph nodes must have been analyzed.
  • Patients with MSI+ tumors (a specific type of tumor) can also be included.
  • All patients must have been discussed in multidisciplinary meetings with a decision not to perform additional chemotherapy.
  • No spread of cancer to other parts of the body as shown by a CT scan or liver MRI within 3 months before joining the study.
  • Joining the study planned up to 11 weeks after surgery with curative intent.
  • WHO performance status less than 2, meaning the patient is able to carry out all normal activities without assistance.

Who cannot join the trial?

4 criteria

  • Patients who do not have **colon carcinoma**. This is a type of cancer that affects the large intestine.
  • Patients who are not within the specified age range for the study.
  • Patients who are not part of the specified clinical trial group.
  • Patients who are part of a vulnerable population, which means they might need special protection or care.
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

FOLFOX6m is a combination chemotherapy treatment used in this clinical trial. It is designed to help improve the chances of being disease-free for patients with colon cancer at stage II who have tested positive for circulating tumor DNA (ctDNA). This treatment combines several drugs that work together to stop cancer cells from growing and dividing, which may help prevent the cancer from coming back after surgery.

What is already known about the treatment

FOLFOX6m – This medication is administered intravenously, typically in a hospital or clinical setting. It is currently being studied in clinical trials for its effectiveness in treating colon cancer, specifically in patients with stage II colon carcinoma. The main therapeutic indication is to improve disease-free survival in patients who test positive for circulating tumor DNA. At the molecular level, FOLFOX6m works by interfering with the DNA replication process in cancer cells, thereby inhibiting their growth and proliferation. It is classified pharmacologically as a chemotherapy regimen, combining several drugs to target cancer cells.

Investigated diseases

Colon Carcinoma – Colon carcinoma is a type of cancer that begins in the large intestine, which is part of the digestive tract. It typically starts as small, noncancerous clumps of cells called polyps that form on the inside of the colon. Over time, some of these polyps can become cancerous. As the disease progresses, it can invade and destroy normal tissue nearby and may spread to other parts of the body. Symptoms often include changes in bowel habits, blood in the stool, and abdominal discomfort. Early stages may not present noticeable symptoms, making regular screenings important for detection.
Trial detailsLast updated 2 Oct 2026
Age18+ yearsPhasePhase IIITrial ID2024-515297-27-00Protocol codePRODIGE 70Estimated enrolment142 patientsSponsorCentre Hospitalier Universitaire De Dijon

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

ClinicalTrials.eu

Every clinical trial in Europe, in plain language.

Explore the full ecosystem of clinical research in Europe.

Search trials

Legal notice · Published by CTIN POLAND sp. z o.o., ul. rtm. Witolda Pileckiego 67/109, 02-781 Warsaw, Poland · KRS 0001111334 · REGON 528919042 · NIP 9512598637

© 2026 Clinical Trials EU – European Clinical Trials Information Network

GDPR compliance, ISO 9001 and ISO 27001 certified (LL-C Certification)

On this site, “treatment” means an investigational medicine being studied in a clinical trial. Its safety and efficacy for the use being studied have not yet been confirmed, some participants may receive a placebo or a comparator medicine, and taking part does not guarantee any health benefit. The decision to take part is made by the doctor at the research site. This site is for information only and does not replace medical advice.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic sites, national regulators and commercial sponsors. On this site, “treatment” and “therapy” mean a medicine being tested in a clinical trial. Its safety and effectiveness in the use being studied are not yet confirmed, some participants may receive a placebo or a comparator, and taking part does not guarantee a health benefit. The doctor at the research site decides who can take part. This site provides information, not medical advice. Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).